(Q39767744)

English

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Carsten Denkert

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Valentina Guarneri

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Pierfranco Conte

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

author name string

V Nekljudova

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

E Holmes

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

C Schem

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

C Sotiriou

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

M Piccart

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

G von Minckwitz

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

S Loibl

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

M Untch

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

J Baselga

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

13 May 2016

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Annals of Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

27

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

1519-1525

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Neoadjuvant treatment of breast cancer: maximizing pathologic complete response rates to improve prognosis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

The PIK3CA gene is mutated with high frequency in human breast cancers.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Reporting recommendations for tumor marker prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW197

21 January 2018

Analysis of PIK3CA mutations in breast cancer subtypes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27177864

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDW197

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27177864%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39767744&oldid=2090112712"